All the news Showing 10 of 23 articles from: EASL 2018Get an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Treatment guidelines New EASL hepatitis C recommendations emphasise simplicity Liz Highleyman / 23 April 2018 The European Association for the Study of the Liver (EASL) released its latest hepatitis C treatment recommendations at the 2018 International Liver Congress this month in Paris. The guidelines are available online in ... Treatment for people living with HIV and HCV Routine clinical use of DAAs highly effective and safe in people with HIV/HCV in Europe Michael Carter / 23 April 2018 “Real life” data from across Europe shows that direct-acting antivirals (DAAs) cure hepatitis C in the vast majority of people with HIV and hepatitis C virus (HCV) co-infection who receive ... Hepatocellular carcinoma (HCC) Large Italian studies confirm no increase in liver cancer risk after hepatitis C treatment Keith Alcorn / 19 April 2018 Further research presented at this year’s International Liver Congress confirms that direct-acting antiviral (DAA) treatment leading to the cure of hepatitis C infection does not raise the risk of developing ... New and experimental treatments for hepatitis B Hepatitis B capsid inhibitors look promising in early studies Liz Highleyman / 18 April 2018 Two experimental drugs that interfere with assembly of the hepatitis B virus (HBV) capsid and prevent production of functional new virus demonstrated good safety and promising antiviral activity in early clinical trials, according ... Treatment outcomes Curing hepatitis C reduces deaths and liver disease Keith Alcorn / 17 April 2018 Curing hepatitis C infection significantly reduces deaths from liver disease and reduces the incidence of decompensation, two large prospective studies from Italy and Scotland show. The findings were presented on ... Genotype 4 HCV treatment feasible and effective in sub-Saharan Africa Keith Alcorn / 17 April 2018 A 12-week course of sofosbuvir/ledipasvir proved highly effective in a sub-Saharan African setting, results of a study carried out in Rwanda show. The findings were presented on Friday at the ... Finance, funding & health economics Early treatment for hepatitis C would be highly cost-effective for Scotland Keith Alcorn / 16 April 2018 Early treatment for hepatitis C is highly cost-effective in Scotland when compared to treatment initiated at the stages of advanced fibrosis or cirrhosis, according to a cost-effectiveness analysis presented on ... Screening policy Active invitation to test for viral hepatitis greatly improves uptake of testing among South Asians in England Keith Alcorn / 16 April 2018 Inviting migrants and their children by post to test for hepatitis B and C in primary care settings results in the identification of a high prevalence of previously undiagnosed infections, ... Pan-genotypic regimens 8-week treatment for hepatitis C with Maviret highly effective in people without cirrhosis Keith Alcorn / 13 April 2018 An eight-week course of treatment with the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C infection in people without cirrhosis, results of two real-world studies presented at the ... Hepatocellular carcinoma (HCC) EASL updates liver cancer guidelines at International Liver Congress Liz Highleyman / 13 April 2018 The European Association for the Study of the Liver (EASL) presented updated clinical practice guidelines for the management of hepatocellular carcinoma (HCC) during a special session at the 2018 International Liver Congress yesterday ... ← Prev123Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive